Definition:Medical stop-loss insurance
🛡️ Medical stop-loss insurance is a form of reinsurance-like protection purchased by employers who self-fund their employee health benefit plans, designed to cap the employer's financial exposure when claims exceed predetermined thresholds. Because self-funded employers assume direct responsibility for paying employees' medical claims — rather than transferring that risk entirely to a health insurer — stop-loss coverage serves as a financial safety net against catastrophic or unexpectedly high aggregate claims. The product is most prevalent in the United States, where a substantial share of large and mid-size employers self-fund their health plans under the framework of the Employee Retirement Income Security Act ( ERISA).
⚙️ Stop-loss insurance operates through two complementary structures. Specific stop-loss (also called individual stop-loss) reimburses the employer when any single covered individual's claims exceed a specified deductible — known as the specific attachment point — during the policy period. Aggregate stop-loss protects against the total plan claims exceeding a predetermined corridor, typically calculated as a percentage of expected claims for the group. Once the aggregate attachment point is breached, the stop-loss carrier reimburses the employer for excess amounts up to the policy limit. Third-party administrators usually handle day-to-day claims adjudication, while the stop-loss carrier monitors claims data and manages the reimbursement process. Pricing relies heavily on the employer's historical claims experience, group demographics, plan design, and the specific and aggregate attachment points selected — with lower attachment points commanding significantly higher premiums.
📊 The medical stop-loss market has grown substantially as self-funding has expanded beyond large corporations into the mid-market and even smaller employer segments, often facilitated by PEOs, association health plans, and insurtech platforms that make self-funding operationally accessible. For carriers and MGAs operating in this space, the challenge lies in accurately modeling large-loss frequency and severity in an environment of rapidly rising specialty drug costs and high-cost medical therapies such as gene therapy. Stop-loss underwriting increasingly leverages predictive analytics and claims data platforms to identify groups with embedded high-cost claimants. While medical stop-loss is fundamentally a U.S. product tied to the American employer-sponsored health system, analogous concepts exist in other markets — for instance, large-deductible group health arrangements in parts of Europe and Asia may incorporate similar excess-of-loss protections, though the regulatory and structural frameworks differ considerably.
Related concepts: